May 17, 2020

Stryker appoints a new head for its India operations

Hospital Leadership
Digital health
medical devices
medical devices
Catherine Sturman
2 min
Leading medical technology company Stryker has revealed that it has appointed Meenakshi Nevatia as the company’s new managing director within its oper...

Leading medical technology company Stryker has revealed that it has appointed Meenakshi Nevatia as the company’s new managing director within its operations in India.

Asia is fast becoming one of the most promising markets. With an ageing population, increased pressures on healthcare organisations are leading health tech companies to view the area’s lucrative, long-term potential, particularly with the launch of its National Health Protection Scheme, Ayushman Bharat.

Responsible for driving the company’s business strategy, and extend the company’s footprint across the Indian market.

With extensive experience working for healthcare giant Novartis, Nevatia is well placed in tackling the challenges which entering a new market will bring to the business.

See also

"Customers and patients are at the heart of everything we do, and I look forward to bringing together our team to do more to improve lives in India," she said.

"I also look forward to creating an environment where our people, one of our core values, can continue to thrive and grow.”

Additionally, Nevatia has a Master in Business Administration in Strategy and Finance from the Indian Institute of Management, Ahmedabad, and Bachelor of Science in Economics and Mathematics from the Presidency College, Kolkata.

The news follows on from the company’s recent acquisition of HyperBranch Medical Technology, Inc., as part of its long-term growth strategy.

Share article

Jun 23, 2021

Introducing Dosis - the AI powered dosing platform

3 min
Dosis is an AI-powered personalised medication dosing platform that's on a mission to transform chronic disease management

Cloud-based platform Dosis uses AI to help patients and clinicians tailor their medication plans. Shivrat Chhabra, CEO and co-founder, tells us how it works. 

When and why was Dosis founded?
Divya, my co-founder and I founded Dosis in 2017 with the purpose of creating a personalised dosing platform. We see personalisation in so many aspects of our lives, but not in the amount of medication we receive. We came across some research at the University of Louisville that personalised the dosing of a class of drugs called ESAs that are used to treat chronic anaemia. We thought, if commercialised, this could greatly benefit the healthcare industry by introducing precision medicine to drug dosing. 

The research also showed that by taking this personalised approach, less drugs were needed to achieve the same or better outcomes. That meant that patients were exposed to less medication, so there was a lower likelihood of side effects. It also meant that the cost of care was reduced. 

What is the Strategic Anemia Advisor? 
Dosis’s flagship product, Strategic Anemia Advisor (SAA), personalises the dosing of Erythropoiesis Stimulating Agents (ESAs). ESAs are a class of drugs used to treat chronic anaemia, a common complication of chronic kidney disease. 

SAA takes into account a patient’s previous ESA doses and lab levels, determines the patient’s unique response to the drug and outputs an ESA dose recommendation to keep the patient within a specified therapeutic target range. Healthcare providers use SAA as a clinical decision support tool. 

What else is Dosis working on? 
In the near term, we are working on releasing a personalised dosing module for IV iron, another drug that’s used in tandem with ESAs to treat chronic anaemia. We’re also working on personalising the dosing for the three drugs used to treat Mineral Bone Disorder. We’re very excited to expand our platform to these new drugs. 

What are Dosis' strategic goals for the next 2-3 years? 
We strongly believe that personalised dosing will be the standard of care within the next decade, and we’re honored to be a part of making that future a reality. In the next few years, we see Dosis entering partnerships with other companies that operate within value-based care environments, where tools like ours that help reduce cost while maintaining or improving outcomes are extremely useful.

What do you think AI's greatest benefits to healthcare are?
If designed well, AI in healthcare allows for a practical and usable way to deploy solutions that would not be feasible otherwise. For example, it’s possible for someone to manually solve the mathematical equations necessary to personalise drug dosing, but it is just not practical. AI in healthcare offers an exciting path forward for implementing solutions that for so long have appeared impractical or impossible.

Share article